Lorenzo's oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder caused by impaired degradation of very long-chain fatty acids (VLCFAs) due to mutations in the ABCD1 gene responsible for VLCFA transport into peroxisomes. Lorenzo's oil, a 4:1 mixture of glyceryl trioleate and glyceryl trierucate, has been used to reduce the saturated VLCFA level in the plasma of X-ALD patients; however, the mechanism by which this occurs remains elusive. We report the biochemical characterization of Lorenzo's oil activity toward elongation of very long-chain fatty acid (ELOVL) 1, the primary enzyme responsible for the synthesis of saturated and monounsaturated VLCFAs. Oleic and erucic acids inhibited ELOVL1, and, moreover, their 4:1 mixture (the FA composition of Lorenzo's oil) exhibited the most potent inhibitory activity. The kinetics analysis revealed that this was a mixed (not a competitive) inhibition. At the cellular level, treatment with the 4:1 mixture reduced the level of SM with a saturated VLCFA accompanied by an increased level of SM with a monounsaturated VLCFA, probably due to the incorporation of erucic acid into the FA elongation cycle. These results suggest that inhibition of ELOVL1 may be an underlying mechanism by which Lorenzo's oil exerts its action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 1×
“The gene mutated in X-ALD is the ABCD1 gene (13) that encodes a peroxisomal”
BackgroundFatty acid elongases in mammals: their regulation and roles in metabolism
JAKOBSSON, A., WESTERBERG, R., & JACOBSSON, A. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.01.004 · Cited by 936
ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis
Ohno, Y., Suto, S., Yamanaka, M., Mizutani, Y., Mitsutake, S., Igarashi, Y., Sassa, T., & Kihara, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005572107 · Cited by 382 · cited 10×
“Among the seven isozymes, ELOVL1 is highly active toward saturated and monounsaturated C20- to C24-CoAs (7) and thus responsible for the synthesis of C22- to C26-VLCFAs such as those accumulated in X-ALD.”
BackgroundMethodInfluentialImgrund, S., Hartmann, D., Farwanah, H., Eckhardt, M., Sandhoff, R., Degen, J., Gieselmann, V., Sandhoff, K., & Willecke, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031971 · Cited by 299
X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283 · cited 2×
“Knockdown of ELOVL1 in X-ALD fibroblasts is reported to lower the level of C26:0 (21), suggesting ELOVL1 as a potential pharmacological target for the treatment of X-ALD (17, 21, 22).”
BackgroundA Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242
Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil
Moser, H. W., Raymond, G. V., Lu, S.-E., Muenz, L. R., Moser, A. B., Xu, J., Jones, R. O., Loes, D. J., Melhem, E. R., Dubey, P., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1073 · Cited by 239 · cited 1×
“Lorenzo’s oil normalizes the levels of C24:0 and C26:0 in the plasma of X-ALD patients (23, 24); however, it does not alter the clinical progression of patients with preexisting neurological or adrenal dysfunction (24, 25) but may have a preventive effect in asymptomatic patients (26).”
BackgroundThe human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl–CoA esters
van Roermund, C. W. T., Visser, W. F., IJlst, L., van Cruchten, A., Boek, M., Kulik, W., Waterham, H. R., & Wanders, R. J. A. (2008) · The FASEB Journal · doi:10.1096/fj.08-110866 · Cited by 233 · cited 1×
“6 ATP-binding cassette (ABC) protein responsible for transporting VLCFAs (as VLCFA-CoAs) into peroxisomes (14, 15) where these FAs are broken down by !-oxidation (16).”
BackgroundDietary erucic acid therapy for X‐linked adrenoleukodystrophy
Rizzo, W. B., Leshner, R. T., Odone, A., Dammann, A. L., Craft, D. A., Jensen, M. E., Jennings, S. S., Davis, S., Jaitly, R., & Sgro, J. A. (1989) · Neurology · doi:10.1212/wnl.39.11.1415 · Cited by 207
Peroxisomal ABC transporters: Structure, function and role in disease
Morita, M., & Imanaka, T. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.009 · Cited by 183 · cited 1×
“6 ATP-binding cassette (ABC) protein responsible for transporting VLCFAs (as VLCFA-CoAs) into peroxisomes (14, 15) where these FAs are broken down by !-oxidation (16).”
Background
Cited by
Metabolism of Very Long-Chain Fatty Acids: Genes and Pathophysiology
Sassa, T., & Kihara, A. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2014.017 · Cited by 302
“…oleic and erucic acids inhibit ELOVL1, suggesting that inhibition of ELOVL1 may be an underlying mechanism by which Lorenzo’s oil exerts its action (Sassa et al., 2014) Peroxisomal b-oxidation of VLCFAs consists of four sequential reactions: dehydrogenation, hydration, dehydrogenation, and…”
Self-citationFatty acid metabolism in the progression and resolution of CNS disorders
Bogie, J. F. J., Haidar, M., Kooij, G., & Hendriks, J. J. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.01.004 · Cited by 167
Chevalier, A. C., & Rosenberger, T. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14032 · Cited by 50
Ferrero, E., Vaz, F. M., Cheillan, D., Brusco, A., & Marelli, C. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109050 · Cited by 24
“…the peroxisomal disorders X-linked adrenoleukodystrophy (OMIM# 300100) and Zellweger disease (OMIM# 214100), where the accumulation of VLCFAs due to impaired degradation has led to the exploration of ELOVL1 inhibitors as potential therapies, aiming at reducing the production of VLCFAs [18,54 – 56].”
Metadata
- Authors
- Sassa, T., Wakashima, T., Ohno, Y., & Kihara, A.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 55
- Issue
- 3
- Pages
- 524-530
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2136141618
- Cited by
- 69
- References
- 14
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.